New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2013
10:55 EDTNBS, NBS, ONVO, ONVO, LIFE, LIFE, GSK, GSK, CELG, CELG, BAX, BAX, STEM, STEM, OSIR, OSIR, BLUE, BLUE, SGMO, SGMO, FCSC, FCSC, PSTI, PSTI, MBLTY, MBLTY, ATHX, ATHX, BTX, BTXAlliance for Regenerative Medicine to hold a meeting
2013 Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 14-16 with webcasted presentations to begin on October 14 at 11 am; not all presentations may be webcasted. Webcast Link
News For NBS;ATHX;MBLTY;PSTI;FCSC;SGMO;BLUE;OSIR;STEM;BAX;CELG;GSK;LIFE;ONVO;BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 29, 2015
10:09 EDTONVOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:56 EDTONVOOrganovo initiated with a Buy at Jefferies
Target $5.
05:41 EDTONVOOrganovo initiated with an Overweight at Piper Jaffray
Subscribe for More Information
June 26, 2015
11:32 EDTCELGCelgene looks to protect itself from Kyle Bass patent challenges, WSJ says
Subscribe for More Information
10:38 EDTGSKCourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
10:04 EDTSTEMStemCells reports top line results for Phase I/II study in dry AMD
Subscribe for More Information
June 25, 2015
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
09:52 EDTPSTIPluristem raises $17M in a registered direct offering
Subscribe for More Information
07:06 EDTBAXMerrimack's MM-398 NDA granted priority review by FDA
Merrimack (MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter (BAX) announced that the New Drug Application for MM-398 has been accepted for review by the FDA. Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. In addition, the FDA has classified the NDA as having Priority Review status. The FDA has set a goal of October 24 to take action under the Prescription Drug User Fee Act. The European Medicines Agency has also accepted for review a Marketing Authorization Application for MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The acceptance of the MAA marks the beginning of the review process in the European Union for MM-398 in this indication.
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
09:07 EDTBLUECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:06 EDTBLUEbluebird bio 2.94M share Spot Secondary priced at $170.00
Subscribe for More Information
05:30 EDTPSTIPluristem granted Australian patent for 3D cell expansion technology
Pluristem Therapeutics announced that it has been granted an Australian patent titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy". Patent #2009288781 covers Pluristem's proprietary, three-dimensional method of growing cells from placental or adipose tissue, cells produced by the process, and the use of such cells in the potential treatment of a broad range of conditions. These include peripheral artery disease, other ischemic and cardiovascular diseases, graft-versus-host disease, organ transplantation, cancer, and autoimmune diseases. The patent term will extend until 2027.
June 23, 2015
18:07 EDTBAXBaxter initiated with a Buy at Goldman
Subscribe for More Information
16:01 EDTBLUEbluebird bio files to sell $400M in common stock
Subscribe for More Information
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:03 EDTBLUEKite Pharma, bluebird bio announce strategic collaboration
Subscribe for More Information
07:05 EDTSTEMStemCells data likely to be positive, says Cantor
Subscribe for More Information
07:01 EDTGSKPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
06:32 EDTBAXKamada collaborates with Baxter on clinical trial with Alpha-1 antitrypsin
Kamada (KMDA) reports that the company has entered into a collaboration with Baxalta International, a wholly-owned subsidiary of Baxter (BAX) on a Phase 1/2 clinical trial of Kamada’s proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Under the agreement, Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016, with more details on trial design to be provided at a later date. Kamada’s proprietary, highly-purified, liquid form of human AAT has shown positive interim results in a proof-of-concept Phase II study in Graft-versus-Host-Disease conducted at the Fred Hutchinson Cancer Research Center in cooperation with Baxalta. Based on those results, preclinical data published in Blood, and at the American Society of Hematology meeting, and a similar mechanism of action, the companies now plan to expand the AAT indication to the prevention of lung transplant rejection and may use this data to support clinical development worldwide. Baxalta has distribution rights to intravenous AAT for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use